Tags

Type your tag names separated by a space and hit enter

Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
Int Urol Nephrol. 2019 Mar; 51(3):519-526.IU

Abstract

PURPOSE

Data concerning the relation between increased levels of circulating sclerostin (a physiological inhibitor of bone formation) and bone turnover in patients with chronic renal failure (CRF) are limited. Therefore, the aim of this study was to evaluate associations between plasma sclerostin levels and calcium-phosphate disturbances, markers of bone turnover as well as inflammation in haemodialysis (HD) patients.

METHODS

In plasma samples obtained in 150 stable HD patients (92 men) aged 40-70 years, levels of sclerostin, fibroblast growth factor (cFGF23), osteocalcin, the N-terminal propeptide of type I procollagen, C-terminal telopeptide of the alpha chain of type I collagen (β-CTx), and inflammatory markers (IL-6 and TNF-α) in addition to routine parameters (calcium, phosphorus, parathyroid hormone-iPTH, 25-OH-D, alkaline phosphatase) were measured.

RESULTS

Plasma sclerostin concentrations were significantly higher in HD men than women (2.61 vs. 1.88 ng/mL, p < 0.01). Patients with sclerostin levels above median were characterized by lower iPTH and IL-6, but higher cFGF23 and TNF-α (significantly only in men) concentrations. Plasma sclerostin concentration positively correlated with serum 25-OH-D (τ = 0.204), phosphorus (τ = 0.1482), and TNF-α (τ = 0.183) and inversely with iPTH (τ = - 0.255), alkaline phosphatase (τ = - 0.203), IL-6 (τ =- 0.201), and β-CTx (τ = - 0.099) levels. In multivariate regression analysis, variability of sclerostin levels was explained by sex and 25-OH-D and phosphorus levels.

CONCLUSIONS

Increased circulating sclerostin levels seem to reflect slower bone turnover in HD patients. Low levels of sclerostin are associated with vitamin D deficiency and good phosphates alignment.

Authors+Show Affiliations

Pathophysiology Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland.Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland.Pathophysiology Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland.Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland.Pathophysiology Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland. chj@poczta.fm. Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia in Katowice, 40-752, Katowice, Poland. chj@poczta.fm.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30584645

Citation

Pietrzyk, Barbara, et al. "Relationship Between Plasma Levels of Sclerostin, Calcium-phosphate Disturbances, Established Markers of Bone Turnover, and Inflammation in Haemodialysis Patients." International Urology and Nephrology, vol. 51, no. 3, 2019, pp. 519-526.
Pietrzyk B, Wyskida K, Ficek J, et al. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Int Urol Nephrol. 2019;51(3):519-526.
Pietrzyk, B., Wyskida, K., Ficek, J., Kolonko, A., Ficek, R., Więcek, A., Olszanecka-Glinianowicz, M., & Chudek, J. (2019). Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. International Urology and Nephrology, 51(3), 519-526. https://doi.org/10.1007/s11255-018-2050-3
Pietrzyk B, et al. Relationship Between Plasma Levels of Sclerostin, Calcium-phosphate Disturbances, Established Markers of Bone Turnover, and Inflammation in Haemodialysis Patients. Int Urol Nephrol. 2019;51(3):519-526. PubMed PMID: 30584645.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. AU - Pietrzyk,Barbara, AU - Wyskida,Katarzyna, AU - Ficek,Joanna, AU - Kolonko,Aureliusz, AU - Ficek,Rafał, AU - Więcek,Andrzej, AU - Olszanecka-Glinianowicz,Magdalena, AU - Chudek,Jerzy, Y1 - 2018/12/24/ PY - 2018/09/27/received PY - 2018/12/07/accepted PY - 2018/12/26/pubmed PY - 2019/8/14/medline PY - 2018/12/26/entrez KW - Calcium–phosphate disturbances KW - Chronic kidney disease-mineral and bone disorder (CKD-MBD) KW - Haemodialysis patients KW - Renal osteodystrophy (ROD) KW - Sclerostin SP - 519 EP - 526 JF - International urology and nephrology JO - Int Urol Nephrol VL - 51 IS - 3 N2 - PURPOSE: Data concerning the relation between increased levels of circulating sclerostin (a physiological inhibitor of bone formation) and bone turnover in patients with chronic renal failure (CRF) are limited. Therefore, the aim of this study was to evaluate associations between plasma sclerostin levels and calcium-phosphate disturbances, markers of bone turnover as well as inflammation in haemodialysis (HD) patients. METHODS: In plasma samples obtained in 150 stable HD patients (92 men) aged 40-70 years, levels of sclerostin, fibroblast growth factor (cFGF23), osteocalcin, the N-terminal propeptide of type I procollagen, C-terminal telopeptide of the alpha chain of type I collagen (β-CTx), and inflammatory markers (IL-6 and TNF-α) in addition to routine parameters (calcium, phosphorus, parathyroid hormone-iPTH, 25-OH-D, alkaline phosphatase) were measured. RESULTS: Plasma sclerostin concentrations were significantly higher in HD men than women (2.61 vs. 1.88 ng/mL, p < 0.01). Patients with sclerostin levels above median were characterized by lower iPTH and IL-6, but higher cFGF23 and TNF-α (significantly only in men) concentrations. Plasma sclerostin concentration positively correlated with serum 25-OH-D (τ = 0.204), phosphorus (τ = 0.1482), and TNF-α (τ = 0.183) and inversely with iPTH (τ = - 0.255), alkaline phosphatase (τ = - 0.203), IL-6 (τ =- 0.201), and β-CTx (τ = - 0.099) levels. In multivariate regression analysis, variability of sclerostin levels was explained by sex and 25-OH-D and phosphorus levels. CONCLUSIONS: Increased circulating sclerostin levels seem to reflect slower bone turnover in HD patients. Low levels of sclerostin are associated with vitamin D deficiency and good phosphates alignment. SN - 1573-2584 UR - https://www.unboundmedicine.com/medline/citation/30584645/Relationship_between_plasma_levels_of_sclerostin_calcium_phosphate_disturbances_established_markers_of_bone_turnover_and_inflammation_in_haemodialysis_patients_ L2 - https://doi.org/10.1007/s11255-018-2050-3 DB - PRIME DP - Unbound Medicine ER -